LONG BEACH, Calif. — In this video, Yasha S. Modi, MD, discusses end-of-study results for EYP-1901 from EyePoint Pharmaceuticals, a bioerodible, sustained-release intravitreal insert to deliver vorolanib for diabetic macular edema.
The phase 2 VERONA study met its primary endpoint, with more than 70% of participants who received high-dose EYP-1901 reaching 24 weeks before needing supplement injection.
“With that said, about one-third of patients still need repeat treatment,” Modi, of NYU Langone Health, told Healio at the American Society of Retina Specialists annual meeting. “So,